Ricevi le ultime notizie sulle azioni Beam Therapeutics con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di BEAM

Ultime notizie per

Beam Inc.

NYSE

Beam Therapeutics

Panoramica

Notizie

Utili

Opzioni

Dividendi

Valutazioni degli analisti

Insider trading

Vendite allo scoperto

Rapporto azionario

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

WIIM

BEAM

Beam Therapeutics shares are trading higher after Evercore ISI initiated coverage on the stock with an Outperform rating and announced a $35 price target.

Comments

Beam Therapeutics Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO